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Abstract
Background: Although routine HIV testing is recommended for jails, little empirical data exist describing newly diagnosed
individuals in this setting.
Methods: Client-level data (CLD) are available on a subset of individuals served in EnhanceLink, for the nine of the 10 sites
who enrolled newly diagnosed persons in the client level evaluation. In addition to information about time of diagnosis, we
analyzed data on initial CD4 count, use of antiretroviral therapy (ART), and linkage to care post discharge. Baseline data from
newly diagnosed persons were compared to data from persons whose diagnoses predated jail admission.
Results: CLD were available for 58 newly diagnosed and 708 previously diagnosed individuals enrolled between 9/08 and 3/
11. Those newly diagnosed had a significantly younger median age (34 years) when compared to those previously
diagnosed (41 years). In the 30 days prior to incarceration, 11% of those newly diagnosed reported injection drug use and
29% reported unprotected anal intercourse. Median CD4 count at diagnosis was 432 cells/mL (range: 22–1,453 cells/mL). A
minority (21%, N=12) of new diagnoses started antiretroviral treatment (ART) before release; 74% have evidence of linkage
to community services.
Conclusion: Preliminary results from a cross-sectional analysis of this cohort suggest testing in jails finds individuals early on
in disease progression. Most HIV
+ detainees did not start ART in jail; therefore screening may not increase pharmacy costs
for jails. Detainees newly diagnosed with HIV in jails can be effectively linked to community resources. Jail-based HIV testing
should be a cornerstone of ‘‘test and treat’’ strategies.
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Introduction
Despite extensive prevention efforts and recommendation for
routine HIV testing, there has been no substantial reduction in the
50,000 new HIV infections annually in the United States [1,2]. Of
the 1.1 million HIV-infected individuals in the United States, 20%
are unaware of their status and it is further estimated that over half
of all new infections are acquired from someone who is unaware of
their infection [2,3]. Identification of HIV is the requisite first step
toward treating HIV and reducing HIV-1 VL levels. Since lower
VL levels are associated with decreased risk for sexual transmission
[4,5], timely ART may be an effective way of reducing new
infections [6], especially if a large proportion of people living with
HIV/AIDS (PLWHA) access treatment early in disease progres-
sion [2]. Most screening in North America, however, does not
diagnose HIV until the disease is advanced. In 2007, the median
value for the first CD4 count after diagnosis in the United States
was 177 cells/mL [7]. A model assessing the impact of increased
treatment coverage on transmission dynamics in at-risk popula-
tions in British Columbia predicts a dramatic reduction in new
cases between 2006 and 2030 if ART coverage is increased above
its current level of 50% among individuals with CD4 counts ,200
cells/mL [8]. Granich et al. used South African data to model an
idealized intervention, where frequent testing and immediate
treatment of 90% of infections would lead to substantial reductions
in new infections [9]. Although other authors using ‘‘more
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could eliminate the HIV epidemic, they agree that more
widespread ART will effectively reduce HIV transmission [10].
Examining how the criminal justice system (CJS) might be
leveraged not only to detect new HIV infections but also engage
HIV-infected persons in care has not yet been fully explored;
however, there is clear evidence that jails can be effective sites to
diagnose new infections and to begin to implement routine care
and prepare for transitional healthcare delivery [11]. The CJS is a
particularly important site to address the HIV epidemic in the
U.S., since drug and alcohol abuse contribute to ongoing HIV
transmission and are highly prevalent in CJS populations
[12,13,14].
Each year, one in six PLWHA in the U.S. spends time within a
CJS facility. Over 90% of persons entering and leaving U.S.
correctional facilities spend time in jails, which are short-term
facilities for persons awaiting trial or sentenced for brief periods of
time, and do not move on to prison [15]. Since most jail inmates
return to the community rather than move on to a prison, jails can
help with continuity of care by having effective transitional
programs for HIV-infected detainees [16].
Former inmates who are HIV-infected, including those who
either are not initiated on ART or who do not remain on it, often
engage in ongoing HIV risk behaviors, which can contribute to
community HIV transmission [17]. Recent data from the HIV
Prevention Trials Network (HPTN 052) support the use of ART to
suppress viral replication and reduce heterosexual HIV transmis-
sion to HIV seronegative sexual partners [18]. ART use among
releasees is critical to reduce transmission to sexual and drug-using
community partners. Recent studies have shown the transition
period from incarceration to community resettlement to be a time
of particularly high risk for cessation of ART with multiple barriers
to ART adherence and filling ART prescriptions [19], which
results in rebounded viral loads [20] and may, in turn, result in
increased risk of transmission to sexual partners.
In 2007 the U.S. Health Resources and Services Administra-
tion’s (HRSA) HIV/AIDS Bureau awarded 10 grants through
their Special Projects of National Significance (SPNS) program to
organizations through the Enhancing Linkages to HIV Primary
Care and Services in Jail Settings Initiative (EnhanceLink). This
initiative sought to implement and evaluate models for linkages to
healthcare for PLWHA who were leaving jails. HIV testing has
been an important aspect of the project; over 180,000 HIV tests
have been conducted across the 10 sites.
As part of the multisite evaluation of the project [21], we
conducted a substudy to assess baseline HIV characteristics and
use of ART among individuals who were newly diagnosed with
HIV in jail and compared them to community-derived samples.
We also assessed linkage to community HIV care among those
released from jail. The overall aim was to provide a detailed
description of a subset of new diagnoses within this setting. A
secondary aim was to statistically compare them demographically
and clinically to those who had previously been diagnosed within
this cohort.
Methods
Ethics statement
The Institutional Review Boards of Rollins School of Public
Health of Emory University and Abt Associates approved the
multisite study. Subsequently, the 10 individual sites’ Institutional
Review Boards approved their individual study involvement. A
certificate of confidentiality was also obtained for the study.
Methodology and analysis
The EnhanceLink study provides an opportunity to gauge how
effective the jail setting can be for the early diagnosis of HIV
followed by prompt linkage to medical care. The 10 diverse
EnhanceLink jail demonstration programs have been previously
described [21]. Briefly, demonstration sites are located in: Atlanta,
GA; Chester, PA; Chicago, IL; Cleveland, OH; Columbia, SC;
New Haven, CT; New York, NY; Philadelphia, PA; Providence,
RI; and Springfield, MA. Most of the jails in EnhanceLink offer
some routine, if not universal, HIV testing.
The EnhanceLink project is collecting two types of information
on project activity. First, each site collected program-level data on a
quarterlybasisfromtheinceptionoftheirinvolvementinthe project
through March 31, 2011. Second, the portion of the project
highlighted here, was the collection of client-level data (CLD) from
approximately 1 in 6 participants. These individuals were
approached and asked to participate in a voluntary evaluation of
their experience in the linkage programs. Sites varied in criteria for
enrollment in the client-level evaluation. While all sites limited
enrollment to persons 18 years or older, one site (New York, NY)
only enrolled persons in the CLD portion of the evaluation whose
diagnosis was made prior to their most recent jail admission. CLD
from the 9 sites eligible for this analysis of newly diagnosed
individuals are available on 781 individuals. Evaluators adminis-
tered a baseline survey to consenting detainees that included
questions on demographic characteristics such as age, sex and race.
Five of the nine sites asked supplemental questions on sexual risk
behavior at the baseline interview. Clients were initially classified as
newly diagnosed if they affirmed on the baseline survey that their
HIV diagnosis was made during their current jail stay. After the
client was released from their index jail stay, clinical data including
CD4 count and plasma VL as measured in commercial laboratories
and conducted in the course of clinical care were extracted from jail
medical records. Six months after release from their index jail stay,
the clients participated in a follow-up survey. For the present
analysis of newly diagnosed clients, we confirmed that there was no
evidence of a prior HIV diagnosis from the jail medical record; we
reclassified clients as previously diagnosed if the chart referred to
HIV-relatedlaboratory tests drawn in the communityprior to index
incarceration. The first CD4 count after diagnosis was examined as
well as whether ART was started before jail discharge and whether
a genotype was requested and reviewed before initiating ART.
Linkage to community HIV care, defined as having either a VL,
CD4 count or both measured within the 6 months post release from
the index incarceration was ascertained from case management
records and review of medical records from community clinics. The
present analysis used data submitted by sites by August 31, 2011;
clients who were deemed ineligible after this date were removed
from the analysis.
The first objective was to describe the CLD of the newly
diagnosed population; descriptive statistics were used. The second
objective was to compare client-level data from the newly
diagnosed detainees to client-level data obtained from detainees
diagnosed prior to their current jail incarceration. Comparisons
with those previously diagnosed were carried out using a two-
sample t-test for continuous outcomes and Pearson chi-square test
for discrete outcomes. Exact tests (Fisher’s) were used where we
had observations on fewer than 5 clients. All analyses were done in
SAS version 9.2 (SAS Institute, Cary, North Carolina).
Results
Across the ten demonstration sites, 210,267 jail detainees were
screened for HIV and 1,312 (0.62%) of tests returned positive; 822
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clients among detainees screened was not uniform across the sites.
Some sites were significantly more likely (p,0.01) to have tests
yielding new diagnoses. The proportion of positive tests at each
site that were new diagnoses ranged between 0.12% and 1.38%.
Program-wide, about 1 in 6 of all persons in the jails who were
known to be HIV positive, including 58 new diagnoses as well as
those already aware of their HIV infections, agreed to participate
in more extensive, individual level evaluation. To our knowledge,
this is the largest program following a group of patients diagnosed
in jail with concurrent individual level data collection.
Demographics
Of the 781 HIV-positive detainees for whom CLD were
collected, we have information on date of diagnosis for 766. Of
these 766, 43% (N=329) were diagnosed initially within a
correctional facility, including the 58 detainees who were first
diagnosed during their current jail stay (See Table 1). The median
age of those newly diagnosed was 33 years. The newly diagnosed
jail detainees were 62% male (N=36), 67% Black (N=39) and
12% (N=7) Hispanic ethnicity. The clients who agreed to provide
CLD had a median jail length of stay of 75 (IQR: 31–147) days.
Data on individual risk behavior were available for 60% (N=35)
newly diagnosed participants and 53% (N=372) previously
diagnosed participants; demographics did not differ significantly
among newly and previously diagnosed participants who provided
risk behavior data. Among newly diagnosed persons, 4 of 35 (11%)
reported a history of injection drug use in the 30 days prior to
index incarceration. Among newly diagnosed men, 7 of 37 (19%)
reported a homosexual or bisexual orientation. Of 24 men
completing the risk behavior component of the survey, 6 (25%)
reported having sex with men in the last 30 days.
Clinical Status
The median CD4 count of the 58 newly diagnosed subjects was
432 (range 22–1,453) cells/mL; 64% had a CD4 count below 500
cells/mL, within the range where DHHS guidelines have become
increasingly more supportive of initiation of ART [22]. Fourteen
percent had an initial CD4 count #200 cells/mL, requiring
prophylaxis for opportunistic infections; 24% had an initial CD4
count of 201–350 cells/mL and 26% had a CD4 count of 351–500
cells/mL. Of the 58 new diagnoses, 21% (N=12) were started on
ART while in jail, 67% (N=39) were not and 12% (N=7) were
missing ART data. The median length of stay for the newly
diagnosed who started ART while in jail was 160 days (IQR: 111–
204 days) three times the median length of stay (49 days) for the
newly diagnosed who did not start ART while in jail. Of the 12
clients started on ART, an HIV genotype was present in the chart
of only 3 (25%) individuals. All 3 of these persons had a length of
stay .2 months. Those who were initiated on ART were
significantly more likely (p,0.01) to have both a CD4 count
below 350 cells/mL and a length of incarceration exceeding 2
weeks compared to those who did not start ART. Of the 35 newly
diagnosed who had been released for at least 6 months and for
whom a six-month follow-up would be expected, 74% (N=26)
had some evidence of medical visits in the community.
Comparison of newly diagnosed and previously
diagnosed
As shown in Table 1, the mean age of those newly diagnosed (34
years) was significantly younger (p,0.01) than those previously
diagnosed (41 years). The newly and previously diagnosed did not
differ in terms of gender, race or ethnicity. There were, however,
significant differences between newly and previously diagnosed
when comparing recent sexual risk taking behavior. Newly
diagnosed clients were more likely to have reported sex with
someone other than their main partner (p,0.01), unsafe vaginal
sex (p=0.01), and unsafe anal sex (p,0.01) in the 30 days prior to
index incarceration as compared to their previously diagnosed
peers.
Newly diagnosed persons were more likely (p,0.01) to have a
history of being employed in the 3 years prior to index
incarceration. A similar proportion of those newly diagnosed
(40%) and of those previously diagnosed (50%) reported visiting an
emergency room within the last 6 months. Newly diagnosed clients
were significantly less likely (p,0.01) to have health insurance at
baseline (health insurance defined as all forms of health benefits,
not just HIV-related benefits) when compared to those previously
diagnosed. There was no significant difference in the likelihood of
having completed a 6-month follow-up medical appointment, or
being linked to medical care post release for those newly diagnosed
(74%) compared to the previously diagnosed detainees (68%, see
Table 1).
Among those previously diagnosed, 78% (N=538) had ever
taken HIV medications and 55% (N=306) were on HIV
medication 7 days prior to their incarceration. About one-third
(38%, N=212) of those previously diagnosed started or restarted
ART while in jail, which was significantly higher (p=0.04) higher
than the proportion starting ART among those newly diagnosed
(24%, N=12) (See Table 1).
Discussion
Results from the EnhanceLink demonstration project suggest
that HIV testing in jails can lead to new diagnoses of HIV
infection and that these infections are being diagnosed substan-
tially early on in the course of the disease. Among the 781 HIV
positive inmates with CLD, the newly diagnosed represent 8%
(N=58). Irrespective of time of HIV diagnosis, nearly one half
(44.3%) of the clients was first diagnosed with HIV in a
correctional facility, either a jail or a prison. The ‘‘correctional
origin’’ of the HIV diagnosis is consistent with other studies
demonstrating the important public health benefit of routine HIV
testing in jails [23,24]. Previous reports have indicated that only a
minority of jail facilities offer routine HIV testing [25,26]. Our
findings suggest that situating testing in jails is feasible and is
associated with HIV detection at an early stage. Implementing
voluntary, opt-out HIV testing in more jails in those regions of the
country most profoundly impacted by the HIV epidemic is
consistent with public health needs.
Based on data from this study, the rapid turnover of jail
detainees is not an impediment to jail-based HIV screening
programs. HIV testing can still be accomplished for large numbers
of detainees. Across all of the EnhanceLink demonstration
projects, including New York, NY, over 180,000 detainees were
screened in the 30 month period between September 2008 and
March 2011. Correctional facilities that have implemented opt-out
testing show substantially increased percentages of individuals
tested [24]. Five of 10 sites in the EnhanceLink project have had at
least one participating jail offer routine opt-out HIV testing at
some point during the project period.
What would be the result of improving availability of HIV
testing in jail facilities across the U.S.? CDC strongly recom-
mended the implementation of jail-based testing in their 2009
guidance on HIV testing in correctional settings [27]. At the
EnhanceLink demonstration sites that provide laboratory data on
newly diagnosed persons, the initial median CD4 count of 432
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CD4 test in 37 states reporting state-wide HIV data to the CDC
(177 cells/mL) [7]. Additionally, the median CD4 cell count of
newly diagnosed detainees in EnhanceLink is greater than the
median CD4 count at presentation estimated from the North
American-AIDS Cohort Collaboration on Research and Design
(NA-ACCORD) in 2007 (317 cells/mL) [28].
The median first CD4 count after diagnosis varies by testing
venue. Table 2 shows median first CD4 counts published in the
literature. The reported median CD4 obtained from individuals
screened in the emergency department context [29,30] was lower
than detainees diagnosed in the EnhanceLink jails. In contrast,
routine testing in a VA Medical System yielded a mean CD4
count of 393 cells/mL [31]. Routine HIV testing in the
Washington State Prison system found that initial CD4 counts
averaged 422 cells/mL [24]. While testing in prisons, like jails,
finds persons early in disease, confining testing just to prisons may
have less impact than testing in all adult correctional facilities,
since seventeen-fold more individuals pass through jails than
prisons [15].
Forty percent of those newly diagnosed persons in our cohort
reported visiting an emergency room at least once in the 6 months
prior to baseline, suggesting that screening within jails can lead to
detection of undiagnosed HIV that may have been missed in other
settings. Consistent with earlier detection, the demonstration sites
are also finding HIV-infected persons at a younger age than found
in other settings. The median age at first diagnosis within the
demonstration sites is substantially younger than the median age at
first diagnosis for the general North American population enrolled
in a consortium of research studies [28].
Identifying HIV infection at an earlier stage is of high priority as
it has significant implications for reducing potential transmission to
drug using and sexual partners and to improving individual health.
Routine HIV screening in jails remains consistent with the
National HIV/AIDS Strategy of increasing the proportion of
PLWHA who know their serostatus from 79% to 90% [32]. The
earlier individuals are aware of their status, the sooner they can be
linked to care and services that would reduce onward transmission
within their communities. Identification of HIV alone has been
associated with a 3–4 fold reduction in sexual risk behaviors even
before implementing targeted interventions [33,34]. Regarding
improved individual health, a recently developed computer
simulation model showed that for persons infected in 2010,
diagnosing HIV early, when the median CD4 count was 432 cells/
mL, rather than late, when median CD4 count had dropped to
140 cells/mL, was associated with 3.5 years greater life expectancy
[35]. Others have shown that when patients present early,
hospitalizations are less frequent and lower costs per patient
persist for over seven years [36,37].
The newly diagnosed individuals in our cohort represent a
riskier group with regards to sexual risk taking behavior than those
already aware of their diagnosis. Newly diagnosed clients were
Table 1. Internal comparison of newly diagnosed and previously diagnosed EnhanceLink jail detainees.
Newly Diagnosed Previously Diagnosed p-value
N( % ) N( % )
Total 58 (8) 708 (92)
Mean age (yrs) 34 (SD=10) 41 (SD=9) ,0.01
Median age (yrs) 33 42
Black Race 39 (67) 436 (64) 0.59
Hispanic ethnicity 7(12) 120 (18) 0.31
Male gender 36 (62) 466 (67) 0.59
Median length of stay in jail (days) 68 76
Among males:
Self-identified as bisexual or homosexual 7 (19) 102 (22) 0.71
Reports sex with men in the past 30 days
+ 6 (25) 26 (12) 0.08
Among both males & females:
Reported unsafe anal or vaginal sex in the past 30 days
+ 21 (60) 96 (27) ,0.01
Reported unsafe anal sex in the past 30 days
+ 10 (29) 34 (9) ,0.01
Reported unsafe vaginal sex in the past 30 days
+ 15 (44) 87 (24) 0.01
Reported sex with someone other than main sex partner in past 30 days
+ 18 (51) 89 (24) ,0.01
Reported use of needles to inject drugs in past 30 days 4 (11) 42 (12) 0.99
In a committed relationship 18 (31) 225 (32) 0.88
Most common employment situation in the past 3 yrs was any kind of work 24 (42) 180 (26) ,0.01
Homeless at index incarceration 25 (43) 311 (44) 0.88
Had some health insurance
++ or benefits to pay for all or part of medical care 20 (35) 462 (66) ,0.01
Started or restarted ART while in jail 12 (24) 212 (38) 0.04
Reported any emergency room visits in the last 6 months 23 (40) 346 (50) 0.15
Any indication of linkage to community care 26 (74) 335 (68.) 0.46
+Obtained from risk behavior module completed by 59% (N=35) of those newly diagnosed and 52% (N=372) of those previously diagnosed.
++Insurance refers to all health insurance, not just HIV-related health insurance.
doi:10.1371/journal.pone.0037603.t001
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than their main partner, unsafe vaginal sex, and unsafe anal sex in
the 30 days prior to index incarceration as compared to their
previously diagnosed peers. This is consistent with evidence
indicating reductions in risky behavior among individuals who
have been diagnosed and are aware that they are HIV-infected
[33,34]. The heightened risky behavior further emphasizes the
need to identify these individuals as early as possible in order to
reduce transmission to others by initiating counseling and ART.
While diagnosing individuals within the CJS represents an
effective public health approach to early detection and HIV
prevention, it likely raises questions within correctional facilities
regarding costs of treating HIV-infected patients once they are
identified. Within this project, most newly diagnosed individuals
did not initiate ART before discharge. There is no evidence that
identifying HIV-infected persons substantially increased pharmacy
costs in this project: approximately 50% of jail detainees are
released in two days [38] and thus most newly diagnosed persons
may leave the facility before a comprehensive pre-treatment
evaluation can be completed. The ideal situation is not to detain a
person in jail longer than legally necessary to initiate ART; the
goal of the EnhanceLink projects was to assure linkage to medical
care, including treatment when indicated, following jail.
For the small percentage of patients who remain in jail long
enough to complete testing and evaluation for the appropriateness
of ART, genotyping, initiation of ART and the subsequent steps of
care provision may also be feasible to begin in jail. Genotype
testing is recommended by the DHHS guidelines before initiating
therapy to identify baseline ART resistance, which affects the
initial choice of ART medications [22]. The majority of newly
diagnosed persons in our cohort who initiated ART before jail
release, however, did not have genotype testing prior to starting
treatment. Taking the time to obtain a genotype may decrease the
number of persons who initiate care before discharge. With such a
large proportion of positive detainees having very short lengths of
stay, the increased cost to jails of offering ART to longer term
detainees should be relatively minimal while making an important
contribution to reducing community viral load. The critical step
for linkage to care, which is the identification of previously
undiagnosed HIV, can begin within jails.
Data on HIV medication either over one’s lifetime or in the 7
days preceding incarceration suggest that the majority of those
previously diagnosed have come off ART prior to incarceration
[39]. Jails therefore serve as an opportunity to re-start ART among
those who have fallen out of care or have come off ART due to
substance use. Data from San Francisco jails show that, among
HIV-positive persons involved in the criminal justice system, those
who use ART only in jail have higher CD4 counts and lower viral
loads compared to those who never use ART [40].
In terms of challenges regarding linkage to care faced by case
managers, not only do they have to support the newly diagnosed
who are coming to terms with their HIV status, but they are also
charged with re-linking those previously diagnosed to care. Our
result showing that 74% of the newly diagnosed had linkage to
HIV care in the community and that the previously diagnosed had
a similar linkage rate demonstrates that EnhanceLink case
managers, in innovative partnership with jails, did an admirable
job linking both population groups to care, despite the challenges
[21].
There are limitations to this study. Data regarding risk
behaviors is cross-sectional, limiting any causal inference—it is
difficult to ascertain temporality. Apart from the laboratory results,
the data are largely verbally self-reported to case-workers or
medical professionals and therefore are subject to social desirabil-
ity bias. The population of detainees who voluntarily provided
CLD is a biased subset skewed towards those with lengths of stay,
who may have more in common with long-term prisoners than the
typical short-term jail detainees; this subset of detainees may not
be representative of HIV-positive jail detainees in general. Yet the
suitability of using the prison setting for HIV interventions is
already well-established [41,42]. Last, while we did report a
relatively high linkage to community services after release based on
our data, further research is needed to determine to what extent
these newly diagnosed persons accessed ART and remained
retained in HIV treatment.
Despite these limitations this is the largest program, to our
knowledge, with concurrent individual level data on jail detainees
Table 2. Published median CD4 counts and median age at first HIV diagnosis.
Median CD4 count Median Age (Year) Study population & design
(cells/mL) (yrs)
356 - (2005–2006) As part of a CDC-funded demonstration project, HIV screening was offered to medically stable patients aged 12
years or older in an urban emergency department located at the Alameda County Medical Center [30].
324 33 (1998–2003) Visit records were reviewed for a cohort of patients who received a new HIV diagnosis between July 1999 and
June 2003. Patients were recruited from an urban academic, an urban community and a suburban community emergency
department located within 10 miles of one another [29].
317 41 (1997–2007) Data were analyzed from 44,491 HIV-infected patients enrolled in the North American-AIDS Cohort Collaboration
on Research and Design identified at first presentation for HIV care. The NA-ACCORD is a multisite collaboration of 8 interval
and 14 clinical cohort studies in the U.S. and Canada [28].
220 36 (2006–2008) Study population consisted of individuals 18 years or older and newly diagnosed with HIV, who had a genotype
done between January 2006 and December 2008 and entered care for the first time at the Henry Ford Hospital located in
downtown Detroit [46]
177 - (2007) Data compiled from 37 states with HIV reporting to the Centers for Disease Control and Prevention (CDC) for at least 4
years. The median CD4 count was compiled from the first CD4 test performed within 3 months after diagnosis of HIV infection
[7].
53 38 (1998–1999) Study population consisted of consecutive newly diagnosed HIV-infected patients from all inpatient and
outpatient HIV tests performed at the Harbor-UCLA Medical Center in California. This hospital serves a primarily urban
minority population including patients at high risk of HIV infection [47].
doi:10.1371/journal.pone.0037603.t002
Early Identification of HIV: Jail-Based Screening
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37603compiled from 9 sites located in different geographic regions
across the U.S. with characteristically different HIV epidemics.
The wide range in the proportion of new diagnoses of all tested
among sites most likely reflects differences in HIV prevalence,
stage of the epidemic, testing policies within correctional facilities
as well as previous availability of testing services within the region,
since yield of testing programs can vary with time [43].
In conclusion, jails remain key sites for diagnosing individuals at
early stages of infection. Public health partnerships, linked to
funding resources, may help to mitigate some of the challenges to
implementation. For example, many of the new criminal justice
‘‘seek, test, and treat’’ models being implemented and tested
around the country are multisectoral partnerships that include
academic medical centers, community-based organizations, and
correctional facilities and clinics [44,45]. Each type of organization
brings to the table needed skills and expertise in identifying,
testing, treating and retaining HIV-infected individuals in care.
The linkage process for jail detainees who are newly diagnosed
HIV positive will be enhanced by evidence-based interventions.
While the multiple needs of those passing through the CJS are
common to individuals in other settings, they may be more
pronounced among those who have been incarcerated. Domains
of need include, in addition to HIV primary care, housing,
transportation, mental health and substance abuse treatment.
Developing effective programs and seamless services that address
these needs will have the best chance of keeping individuals in
care. In summary, testing in jails is feasible, pharmacy costs for
jails may be manageable and linkage to care upon discharge is
achievable.
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